Takeda Rozerem Clinical Significance Debated In FDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The "curious" failure of subjective secondary endpoints to agree with the efficacy of Takeda’s Rozerem on objective sleep measures contributed to a debate at FDA over the clinical significance of the insomnia therapy.